AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance

Abstract

Advances in artificial intelligence (AI) have revolutionized cancer follow-up monitoring, offering opportunities to enhance the early detection of recurrences, streamline survivorship care, and personalize monitoring protocols. This article reviews the current landscape of AI-based cancer follow-up, examining epidemiology, mechanisms, clinical features, diagnostic strategies, treatment implications, recent advances, and evidence-based guideline recommendations. Emphasis is placed on the integration of machine learning algorithms, real-world clinical applications, and future directions for optimizing patient outcomes.

Introduction

Cancer survivorship is a rapidly expanding domain, with millions of individuals worldwide requiring long-term monitoring to detect recurrence, manage treatment sequelae, and optimize quality of life. Traditional follow-up models predominantly rely on scheduled visits and imaging, often resulting in over- or under-utilization of healthcare resources. AI-based approaches promise to transform this paradigm by leveraging large datasets, advanced algorithms, and automated decision-support tools for tailored, risk-adapted surveillance. Integrating AI into cancer follow-up represents a paradigm shift toward precision medicine, offering the potential to improve outcomes while enhancing efficiency and reducing patient burden.

Epidemiology / Disease Burden

Cancer incidence continues to rise globally, with over 19 million new cases and nearly 10 million deaths reported in 2022. Improvements in screening, diagnostics, and therapy have increased survivorship, with an estimated 43 million cancer survivors worldwide. The growing survivor population intensifies demands on follow-up care systems, challenging clinicians to balance the need for vigilance with the risks of overtreatment. Current follow-up protocols are often standardized by tumor type but lack personalization to individual risk profiles, which may lead to unnecessary testing or missed early recurrences. AI-driven monitoring addresses these limitations by harnessing population-level and individual data to stratify risk and tailor follow-up intensity.

Pathophysiology

Cancer recurrence and progression are driven by complex biological processes, including residual microscopic disease, genetic and epigenetic alterations, and interactions within the tumor microenvironment. The heterogeneity of these mechanisms complicates reliable prediction of relapse using conventional clinical factors alone. AI methodologies, particularly deep learning and neural networks, can analyze multi-dimensional data such as genomics, radiomics, and digital pathology to identify subtle patterns indicative of recurrence risk. These tools enable mechanistic insights and facilitate earlier intervention compared to traditional methods.

Risk Factors

Risk stratification in cancer follow-up relies on factors including tumor histology, stage at diagnosis, treatment modalities, molecular markers, and comorbidities. AI-powered models can synthesize these variables alongside patient demographics, lifestyle factors, and real-time health data from electronic health records (EHRs) or wearable devices. Such comprehensive risk assessment allows the creation of adaptive surveillance schedules, ensuring high-risk patients receive intensified monitoring while minimizing unnecessary interventions for low-risk individuals. This approach is particularly relevant for cancers with variable recurrence patterns, such as breast, colorectal, and prostate malignancies.

Clinical Features

Clinical features of recurrence may be subtle or nonspecific, such as fatigue, weight loss, or localized pain, which can be easily overlooked in routine follow-up visits. AI-based systems can aggregate and interpret longitudinal patient-reported symptoms, laboratory data, and imaging findings, alerting clinicians to early warning signs. Natural language processing (NLP) algorithms can extract relevant information from clinical notes and correspondence, further enhancing the detection of clinically significant changes that may otherwise be missed.

Diagnosis

Diagnostic accuracy in cancer follow-up is critical to timely intervention. AI algorithms have demonstrated proficiency in interpreting imaging modalities—such as CT, MRI, and PET scans—with sensitivity and specificity comparable to expert radiologists. Automated segmentation, radiomic feature extraction, and anomaly detection algorithms facilitate early identification of suspicious lesions. Additionally, AI can aid in the interpretation of circulating tumor DNA (ctDNA), proteomics, and other liquid biopsy markers, supporting the noninvasive monitoring of minimal residual disease and molecular relapse.

Treatment & Management

AI-based follow-up does not replace clinical judgment but augments decision-making by providing risk-adapted recommendations. For patients with detected recurrence, AI-driven tools can suggest individualized diagnostic and therapeutic pathways based on up-to-date guidelines and real-world evidence. Integration with multidisciplinary tumor boards and clinical workflow platforms enables efficient escalation of care, shared decision-making, and patient engagement. Importantly, AI can facilitate the identification of candidates for novel therapies, clinical trials, or early supportive care interventions, improving the continuum of survivorship care.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of AI-powered platforms such as DeepSurv, OncoPredict, and Watson for Oncology, which utilize machine learning to predict recurrence risk and optimize follow-up strategies. Studies have demonstrated the utility of convolutional neural networks (CNNs) for imaging surveillance in lung, breast, and colorectal cancers. AI-driven real-time symptom monitoring and telehealth integration have shown promise in reducing hospitalizations and improving patient-reported outcomes. Furthermore, federated learning approaches enable multi-institutional model training while preserving data privacy, accelerating the translation of AI research into clinical practice.

Guideline Recommendations

Professional societies, including ASCO, ESMO, and NCCN, increasingly acknowledge the role of digital health and AI in cancer survivorship. Current guidelines recommend risk-adapted follow-up and support the incorporation of validated AI tools to complement clinical assessment, provided these systems are transparent, interpretable, and subject to ongoing evaluation. Regulatory bodies emphasize the importance of clinician oversight, data security, and patient consent in the deployment of AI-based monitoring solutions. Ongoing multicenter trials and real-world implementation studies will further inform evidence-based recommendations and best practices.

Conclusion

AI-based cancer follow-up monitoring heralds a transformative era in survivorship care, enabling precision surveillance, early detection of relapse, and personalized management. By integrating advanced algorithms with clinical workflows, these technologies address the challenges of rising survivorship, healthcare resource constraints, and the need for individualized care. Continued research, validation, and responsible implementation are essential to realizing the full potential of AI in optimizing long-term cancer outcomes and enhancing the patient experience.